

# Evaluation of Gastrointestinal Patient Reported Outcomes Measurement Information System (GI-PROMIS) Symptom Scales in Subjects With Inflammatory Bowel Diseases

Bharati Kochar, MD, MSCR<sup>1</sup>, Christopher F. Martin, MSPH<sup>1</sup>, Michael D. Kappelman, MD, MPH<sup>1</sup>, Brennan M. Spiegel, MD, MSHS<sup>2</sup>, Wenli Chen, MS, MA<sup>1</sup>, Robert S. Sandler, MD, MPH<sup>1</sup> and Millie D. Long, MD, MPH<sup>1</sup>

- OBJECTIVES:** Patient reported outcomes (PROs) are important treatment endpoints in inflammatory bowel diseases (IBD). We evaluated the gastrointestinal (GI) PRO Measurement Information System (PROMIS) in IBD subjects.
- METHODS:** Crohn's and Colitis Foundation of America's Partners is an Internet-based cohort of IBD subjects. Participants complete surveys, including demographics, disease characteristics, PROMIS domains, disease activity (short Crohn's disease activity index or simple clinical colitis activity index) and quality of life (QoL) indices. In a nested cross-sectional study, we used univariate and bivariate analyses to assess associations between 8 GI-PROMIS domains (reflux, swallowing, diarrhea, nausea, belly pain, gas, incontinence, and constipation) and QoL and disease activity indices.
- RESULTS:** The study included 2,378 Crohn's Disease (CD) and 1,455 ulcerative colitis (UC) respondents with a median age of 41 years. Median disease duration was 11 years for CD subjects and 8 years for UC subjects; 57% of CD subjects and 42% of UC subjects were in remission. Among symptomatic CD subjects, those with active CD reported significantly worse symptoms on all 8 domains than those in remission. The same was observed for UC subjects with the exception of disrupted swallowing. IBD subjects with worse QoL reported significantly worse symptoms on all 8 domains compared to those with better QoL.
- CONCLUSIONS:** In IBD subjects experiencing GI symptoms, GI-PROMIS domains were strongly associated with disease activity and QoL indices. GI-PROMIS holds potential as PRO measures in IBD and correlates with other validated indices in this population.

*Am J Gastroenterol* advance online publication, 29 August 2017; doi:10.1038/ajg.2017.240

## INTRODUCTION

In patients with inflammatory bowel diseases (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC), common symptoms include diarrhea, abdominal pain, or rectal bleeding (1–4). However, other gastrointestinal and psychosocial symptoms may be present, particularly when disease is active. Many of these additional symptoms impact patients physically and emotionally and have a negative impact on quality of life (5,6). These symptoms are legitimate targets for treatments. Various symptom scales

have been studied to assess the efficacy of IBD treatment (7–10). The Food and Drug Administration (FDA) has determined that for clinical trials of IBD treatments, co-primary endpoints of patient reported outcomes (PROs) and endoscopic endpoints are required. While candidate PRO measures have been proposed, a complete inventory of GI symptoms using validated PRO scales has not been available.

IBD patients are reported to commonly have psychosocial symptoms such as depression and anxiety (11,12). Results of one

<sup>1</sup>Center for Gastrointestinal Biology & Disease, University of North Carolina, Chapel Hill, North Carolina, USA; <sup>2</sup>Division of Gastroenterology, Cedars-Sinai Medical Center, Los Angeles, California, USA. **Correspondence:** Millie D. Long, MD, MPH, Division of Gastroenterology and Hepatology, University of North Carolina, Campus Box #7080, 130 Mason Farm Road, Chapel Hill, North Carolina 27599-7080, USA. E-mail: millie\_long@med.unc.edu

Received 21 January 2017; accepted 26 June 2017

prospective cohort study suggest that depressive symptoms may increase the risk for CD among women (13). Additionally, depression has been shown to impact the course of IBD and is associated with worsened disease activity and complications (14). Furthermore, psychological symptoms can pose treatment barriers (15). However, there are no data to indicate how specific gastrointestinal symptoms correlate with psychosocial symptoms in patients with IBD.

PROs are important factors in understanding the burden of IBD. There are a full range of GI symptoms that contribute to the burden of IBD. The National Institutes of Health's Patient Reported Outcomes Measurement Information System (PROMIS) is a publically available, standardized set of PROs that cover physical, mental and social health. Recently, eight scales were developed for GI symptom domains under this framework (16). There is a greater need for the use of PROs to advance the understanding of symptoms in IBD patients. PROs can also be used both in clinical practice and in clinical trials as important endpoints. In this study, we aimed to determine whether GI-PROMIS domains can be used to assess symptoms in IBD patients.

## METHODS

### Study setting

The Crohn's and Colitis Foundation of America (CCFA) Partners study is a longitudinal Internet-based cohort of people living with IBD. The development of this cohort has been described in detail previously (17). In brief, we recruited participants with a self-reported diagnosis of CD, UC or indeterminate colitis (IC) who were 18 years of age or older through CCFA e-mail rosters, websites, various social media outlets, and at educational and fundraising events. To date, the cohort has enrolled over 15,000 individuals with IBD. All participants completed a baseline survey including demographic information, questions about their IBD history, symptoms and medication use. Respondents then complete bi-annual surveys to update disease and demographic information. CCFA Partners surveys include a number of validated IBD activity indices, quality of life measures and PROMIS assessments as described below.

### Instruments

The GI-PROMIS scales assess 8 domains: gastroesophageal reflux (13 items), disrupted swallowing (7 items), diarrhea (5 items), bowel incontinence/soilage (4 items), nausea and vomiting (4 items), constipation (9 items), belly pain (6 items), and gas/bloat/flatulence (12 items) (16). All scales are reported in percentiles, among individuals who report that symptom.

The psychosocial PROMIS scales assess 6 domains: anxiety (4 items), depressive symptoms (4 items), fatigue (4 items), pain interference (4 items), social satisfaction (4 items) and sleep disturbance (4 items) (18). All scales are calibrated using an item response theory graded response model and scored on a T-score metric with a mean of 50 and standard deviation (s.d.) of 10 in the US general population. A higher score denotes more symptoms on that scale, with the exception of social satisfaction, where a lower

score indicates better social satisfaction. Based on prior data in chronic diseases, a minimally important difference (MID) for the psychosocial scales is 2–3 points (19).

Disease activity instruments were also completed by participants at the time of the PROMIS scales. Subjects with CD completed the short Crohn's Disease Activity Index (sCDAI); on this scale, remission is defined as a score <150. Ulcerative colitis or indeterminate colitis subjects completed the Simple Clinical Colitis Activity Index (SCCAI); remission is defined as a score ≤2. The short Inflammatory Bowel Disease Questionnaire (SIBDQ) is a measure of quality of life, a lower score indicates a worse quality of life.

### Study design

We performed a cross-sectional analysis of IBD subjects enrolled in CCFA Partners from January 2015 to April 2016 who answered GI and psychosocial PROMIS domains. We stratified subjects by factors such as surgical status, disease activity, and disease duration. We also assessed PROMIS domains by classes of medications.

### Statistical analysis

We used descriptive statistics and bivariate analyses to evaluate GI-PROMIS measures relative to validated instruments such as the sCDAI, SCCAI and SIBDQ (20,21). We conducted a sensitivity analysis including only UC patients who have not undergone surgery. All analyses were performed in STATA 14.0 (College Station, TX). The study protocol was approved by the institutional review board at the University of North Carolina at Chapel Hill.

## RESULTS

### Demographics

There were 2,378 subjects with CD (**Table 1a**) and 1,455 subjects with UC (**Table 1b**; the IC patients were included with UC), who completed GI-PROMIS questionnaires. Respondents were predominantly female and white: 74% of CD and 72% of UC subjects were female; 95% of CD subjects and 92% of UC subjects were white. A total of 72% of CD subjects and 77% of UC subjects reported a college degree or greater. The median age was 41 years for CD subjects (interquartile range (IQR): 29–54) and UC subjects (IQR: 31–53). Median disease duration was 11 years (IQR: 4–22) for CD subjects and 8 years (IQR: 3–15) for UC subjects. Most of the respondents had previously been hospitalized: 82% of CD subjects and 62% of UC subjects. Half of the CD subjects and 11% of UC subjects had previous surgery for IBD. At the time of the questionnaire, 57% of CD subjects and 42% of UC subjects were in remission.

### GI-PROMIS in subjects with Crohn's disease

Among CD respondents, 24% reported reflux, 9% reported difficulty swallowing, 52% reported diarrhea, 44% reported nausea and vomiting, 43% reported belly pain, 59% reported gas, 16% reported bowel incontinence and 15% reported constipation (**Figure 1**). Symptomatic CD subjects reported a higher level of symptoms than symptomatic subjects in the general population

**Table 1a. Characteristics of the population with Crohn's disease**

Characteristic	Crohn's disease, (n=2,378) % or median (IQR)
% Female	74
Age (years)	41 (29–54)
<i>Race</i>	
% White	95
% Black	1
% College graduate or greater	72
Body mass index (BMI)	24 (22–29)
% Current smokers	7
Disease duration (years)	11 (4–22)
<i>% Currently used medications</i>	
Corticosteroids	13
Mesalamine agents	26
Immunomodulators	29
Anti-TNF Biologicals	49
Probiotics	26
Antibiotics	4
Narcotics	12
% With a prior IBD hospitalization	82
% With prior IBD surgery	50
Disease activity (% remission <sup>a</sup> )	57
SIBDQ	5.0 (3.9–5.8)
IBD, inflammatory bowel diseases; IQR, interquartile range; SIBDQ, short inflammatory bowel disease questionnaire; TNF, tumor necrosis factor.	
<sup>a</sup> Defined as a short Crohn's disease activity index (sCDAI) <150.	

**Table 1b. Characteristics of the population with ulcerative colitis**

Characteristic	Ulcerative colitis, (n=1455) % of median (IQR)
% Female	72
Age (years)	41 (31–53)
<i>Race</i>	
% White	92
% Black	1
% College graduate or greater	77
Body mass index (BMI)	25 (22–29)
% Current smokers	3
Disease Duration (years)	8 (3–15)
<i>% Currently Used Medications</i>	
Corticosteroids	13
Mesalamine agents	59
Immunomodulators	22
Anti-TNF Biologicals	26
Probiotics	31
Antibiotics	3
Narcotics	6
% With a prior IBD hospitalization	62
% With prior IBD surgery	11
Disease activity (% remission <sup>a</sup> )	42
SIBDQ	5.2 (4.1–5.9)
IBD, inflammatory bowel diseases; IQR, interquartile range; SIBDQ, short inflammatory bowel disease questionnaire; TNF, tumor necrosis factor.	
<sup>a</sup> Defined as a Simple Clinical Colitis Activity Index (SCCAI) <2.	

(54th percentile for diarrhea, 57th percentile for nausea and vomiting, 55th percentile for belly pain, 53rd percentile for gas, 56th percentile for bowel incontinence and 53rd percentile for constipation; **Figure 2**).

#### GI-PROMIS in subjects with ulcerative colitis

Among UC respondents, 9% reported reflux, 3% reported difficulties swallowing, 17% reported diarrhea, 8% reported nausea and vomiting, 19% reported belly pain, 27% reported gas, 6% reported bowel incontinence and 7% reported constipation (**Figure 1**). Symptomatic UC subjects reported similar degrees of symptoms compared to symptomatic subjects in the general population (50th percentile for diarrhea, 49th percentile for belly pain and 48th percentile for constipation; **Figure 2**). Similar trends were seen in a sub-group analysis of UC subjects who did not have surgery.

#### Differences by surgical status

Compared to CD subjects who did not have prior surgery for CD, those who had surgery reported more diarrhea ( $P<0.01$ ), belly pain ( $P=0.02$ ), gas ( $P=0.04$ ) and bowel incontinence ( $P<0.01$ ).


There were no meaningful differences between UC subjects based on surgical status.

#### Differences by disease activity, quality of life and psychosocial measures


Among symptomatic CD subjects, those with active disease reported significantly more symptoms on all 8 GI-PROMIS domains than those in remission (**Table 2a**). With the exception of disrupted swallowing, symptomatic UC subjects with active disease also reported significantly more symptoms on the other 7 GI-PROMIS than UC subjects in remission (**Table 2b**).

When stratified by quartiles of the SIBDQ, symptomatic CD and UC subjects in the lowest quartile (worst quality of life) reported significantly more symptoms on all 8 GI-PROMIS domains compared to those in the highest quartile (best quality of life). There was a trend toward decreasing GI symptoms with higher SIBDQ scores (**Table 3**).

Respondents who reported more symptoms on the GI-PROMIS domains reported significantly more symptoms on the psychosocial PROMIS domains. We present data from three representative domains, diarrhea, belly pain and gas. Amongst CD subjects,



**Figure 1.** Prevalence of gastrointestinal symptoms in patients with inflammatory bowel diseases (IBD) as measured by GI-PROMIS scales.



**Figure 2.** Gastrointestinal Patient Reported Outcome Measurement Information System (GI-PROMIS) symptom scales in symptomatic subjects with inflammatory bowel disease (domains are reported as percentiles compared to all those in the general population who reported that symptom).

**Table 2a. Gastrointestinal Patient Reported Outcome Measurement Information System (GI-PROMIS) domain percentiles stratified by remission status for symptomatic subjects with Crohn's disease**

	Active disease (n=1,023)	Remission (n=1,355)	P-value
Reflux	63	44	<0.01
Swallowing	59	46	<0.01
Diarrhea	67	40	<0.01
Nausea and vomiting	63	42	<0.01
Belly pain	68	37	<0.01
Gas/bloat/flatulence	67	42	<0.01
Bowel incontinence	63	44	<0.01
Constipation	64	48	<0.01

Remission in Crohn's disease defined as a short Crohn's Disease Activity Index (sCDAI) <150.

**Table 2b. Gastrointestinal Patient Reported Outcome Measurement Information System (GI-PROMIS) domain percentiles stratified by remission status for symptomatic subjects with ulcerative colitis**

	Active disease (n=844)	Remission (n=611)	P-value
Reflux	50	36	<0.01
Swallowing	51	39	0.09
Diarrhea	58	26	<0.01
Nausea and vomiting	52	37	<0.01
Belly pain	55	33	<0.01
Gas/bloat/flatulence	55	39	<0.01
Bowel incontinence	54	29	<0.01
Constipation	56	36	<0.01

Remission in ulcerative colitis defined as Short Clinical Colitis Activity Index (SCCAI) <2.

in general, those who had more GI symptoms reported significantly more psychosocial symptoms than those who had less GI symptoms compared to those who did not report any GI symp-

oms (**Table 4a**). In the UC cohort, those who had more GI symptoms reported significantly more psychosocial symptoms than those who had less GI symptoms; however, those who had less GI

**Table 3.** Gastrointestinal Patient Reported Outcome Measurement Information System (GI-PROMIS) percentiles in symptomatic inflammatory bowel disease subjects stratified by quartiles of the Short Inflammatory Bowel Disease Questionnaire (SIBDQ)

	GI-PROMIS domain percentiles				
	Crohn's disease				
	SIBDQ quartile 1 (1–2.9, n=551)	SIBDQ quartile 2 (4–5, n=612)	SIBDQ quartile 3 (5.1–5.8, n=566)	SIBDQ quartile 4 (5.9–7, n=642)	P-value
Reflux	69	52	48	33	<0.01
Disrupted swallowing	70	49	38	41	<0.01
Diarrhea	77	59	44	28	<0.01
Nausea and vomiting	72	53	45	30	<0.01
Belly pain	80	56	40	28	<0.01
Gas/bloat/flatulence	76	61	47	30	<0.01
Bowel incontinence	68	56	49	36	<0.01
Constipation	69	57	45	40	<0.01
	Ulcerative colitis				
	SIBDQ quartile 1 (1–4.1, n=319)	SIBDQ quartile 2 (4.2–5.2, n=398)	SIBDQ quartile 3 (5.3–5.9, n=336)	SIBDQ quartile 4 (6–7, n=394)	P-value
Reflux	61	55	34	32	<0.01
Disrupted swallowing	65	50	40	25	<0.01
Diarrhea	77	50	36	24	<0.01
Nausea and vomiting	61	49	44	25	<0.01
Belly pain	73	50	35	26	<0.01
Gas/bloat/flatulence	73	54	40	30	<0.01
Bowel incontinence	63	50	42	33	<0.01
Constipation	72	49	39	32	<0.01

GI-PROMIS percentiles cannot be calculated in persons not experiencing a given symptom.

symptoms reported psychosocial symptoms in the same range as those who did not have any GI symptoms (Table 4b).

#### Differences by narcotic use

Symptomatic CD subjects on narcotics reported significantly more symptoms on all 8 GI-PROMIS domains compared to those not on narcotics. Symptomatic UC subjects on narcotics reported more reflux (68th percentile vs. 45th percentile,  $P<0.01$ ), diarrhea (71st percentile vs. 48th percentile,  $P<0.01$ ), nausea and vomiting (66th percentile vs. 48th percentile,  $P<0.01$ ), belly pain (65th percentile vs. 47th percentile,  $P<0.01$ ) and gas (69th percentile vs. 47th percentile,  $P<0.01$ ) compared to those not on narcotics.

## DISCUSSION

Patient reported outcomes (PROs) are an essential component of patient centered research. The GI-PROMIS scales are a recent addition to the PROMIS portfolio that are freely available to the public free of charge, low burden for patients to complete and capable of implementation in clinical practice (22). We present data on GI-PROMIS scales in a large cohort of subjects with

IBD. Within the IBD population, there were strong associations between worsened GI symptoms and worsened quality of life, disease activity and psychosocial symptoms.

There have been few studies comparing the prevalence of gastrointestinal symptoms in IBD subjects to those of the general population (23,24). We found that symptomatic IBD subjects report GI symptoms in the same range as the general population who report these symptoms. In essence, regardless of the cause of the symptom (such as diarrhea), subjects with IBD and those without IBD report a similar symptom burden. There were no notable differences when stratified by age, gender or disease duration. It is possible that IBD subjects are accustomed to GI symptoms and have been able to accommodate over time. This finding may also reflect disease control. A sub-group analysis confirmed that those who had active disease reported worsened GI symptoms when compared to those in remission, with the exception of disrupted swallowing in UC subjects. These findings are in line with a prior study demonstrating a high symptom burden in IBD patients. This study also demonstrated that while many patients with inactive disease report GI symptoms, the symptoms burden was highest amongst patients with active IBD (25).

**Table 4a.** Association between gastrointestinal symptoms and psychosocial Patient Reported Outcome Measurement Information System (PROMIS) domains in Crohn's disease

Psychosocial PROMIS Domains	GI-PROMIS Domain		
	No diarrhea (n=578)	Low diarrhea (n=569)	High diarrhea (n=536)
Anxiety	50	50	57
Depressive symptoms	48	49	55
Fatigue	51	54	62
Pain interference	48	50	58
Sleep disturbance	52	52	52
Social Satisfaction	52	51	43
	No belly pain (n=748)	Low belly pain (n=465)	High belly pain (n=460)
	Anxiety	49	52
Depressive symptoms	48	50	56
Fatigue	50	55	64
Sleep disturbance	52	52	52
Social satisfaction	53	50	42
	No gas (n=380)	Low gas (n=647)	High gas (n=635)
	Anxiety	50	50
Depressive symptoms	48	48	55
Fatigue	51	52	61
Pain interference	49	48	57
Sleep disturbance	52	52	52
Social satisfaction	52	52	45

The numbers in the table are T scores. The psychosocial PROMIS domains are scored on a T-score metric with a mean of 50 and standard deviation (s.d.) of 10 in the United States general population. A higher score denotes more symptoms on that scale, with the exception of social satisfaction, where a lower score indicates better social satisfaction. A minimally important difference (MID) for the psychosocial scales is 2–3.

Low and high gastrointestinal (GI) symptoms divided at the median reported on the GI-PROMIS scales.

It is notable that IBD subjects report levels of gastrointestinal symptoms similar to the general population in all domains, including those not traditionally associated with IBD, such as reflux and disrupted swallowing. Prior research has shown that people with medically unexplained symptoms, such as an ulcerative colitis patient who has reflux or a Crohn's patient who has disrupted swallowing, report more symptoms when recalling a 7 day period compared to people who do not have as many medically unexplained symptoms (26). It is possible that poorly controlled IBD may result in a variety of previously unrecognized symptoms due to a lack of awareness from patients and providers alike. It is also possible that individuals with IBD have a perception of poor overall gastrointestinal health, thus reporting symptoms in all categories.

**Table 4b.** Association between gastrointestinal symptoms and psychosocial Patient Reported Outcome Measurement Information System (PROMIS) domains in ulcerative colitis

Psychosocial PROMIS Domains	GI-PROMIS domain		
	No diarrhea (n=533)	Low diarrhea (n=274)	High diarrhea (n=206)
Anxiety	50	51	57
Depressive symptoms	48	49	55
Fatigue	51	53	60
Pain interference	48	50	58
Sleep disturbance	52	52	52
Social Satisfaction	53	51	43
	No belly pain (n=475)	Low belly pain (n=322)	High belly pain (n=212)
	Anxiety	49	53
Depressive symptoms	48	50	55
Fatigue	49	53	61
Sleep disturbance	52	52	52
Social satisfaction	54	50	43
	No gas (n=251)	Low gas (n=431)	High gas (n=317)
	Anxiety	49	50
Depressive symptoms	47	48	54
Fatigue	50	51	59
Pain interference	48	48	55
Sleep disturbance	52	52	52
Social satisfaction	53	52	46

The numbers in the table are T scores. The psychosocial PROMIS domains are scored on a T-score metric with a mean of 50 and standard deviation (s.d.) of 10 in the United States general population. A higher score denotes more symptoms on that scale, with the exception of social satisfaction, where a lower score indicates better social satisfaction. A minimally important difference (MID) for the psychosocial scales is 2–3.

Low and high gastrointestinal (GI) symptoms divided at the median reported on the GI-PROMIS scales.

Prior studies have shown the association between depression/anxiety and treatment adherence, worsening symptoms of IBD and general social functioning (6,15,27,28). We demonstrate that those subjects with worsened GI symptoms on the PROMIS scales also report worsened psychosocial symptoms, namely depression, anxiety, pain interference, fatigue, social satisfaction and sleep disturbance. For both CD and UC subjects, minimal levels of GI symptoms did not increase psychosocial symptoms when compared to those without GI symptoms. However, those who have high levels of GI symptoms report psychosocial symptoms that are meaningfully higher than reference populations. In summary, those with well controlled GI symptoms are similar to those who are asymptomatic, but those with poorly controlled GI symptoms have worsened psychosocial symptoms.

In a sub-group analyses by SIBDQ and disease activity indices, those subjects who reported worsened quality of life and disease activity also reported worsened GI symptoms for all eight GI-PROMIS scales. This supports the fact that the PROMIS scales are good measures of GI symptoms in IBD subjects and are responsive to differences in disease activity. However, it should be noted that these disease activity measures include symptoms and therefore, it is not surprising that they do correlate so well.

While there are data on the harmful effects of narcotics in patients with IBD (29,30), there are no specific reports correlating narcotics with worsening GI symptoms, as we demonstrate. It is possible that use of narcotics is a marker of poorly controlled IBD (31), explaining the presence of worsened GI symptoms. It is also possible that use of narcotics is a marker for poorly controlled symptoms of irritable bowel syndrome (IBS), which can be prevalent in IBD patients (24,32). Finally, it is possible that narcotics themselves could paradoxically worsen various GI symptom measures, perhaps through mechanisms of alternation of motility.

There are several strengths of this study, including the large sample size and geographically diverse population. However, there are limitations as well. Primarily, this is a cross-sectional study, which precludes the ability to determine causality. The demographics of the population, predominantly female, white and well-educated, does not reflect the IBD population across the US. Therefore, the CCFA-Partners Internet-based cohort is not representative of the US IBD population. This cohort focuses on patient reported information without individualized confirmation from a medical record. However, a validation study from a subset of this cohort revealed 97% concordance between self-reported diagnosis of IBD and evaluation of the medical record (33). In addition, the self-reported data collection should not affect the reliability of the responses for the PROMIS scales.

In conclusion, this cross-sectional analysis is the first report of the previously validated GI-PROMIS scales in a large sample of IBD subjects. These measures were found to correlate with other validated scales of quality of life and disease activity. Furthermore, higher percentiles on a GI-PROMIS domains correlate with worse psychosocial PROs in this IBD population. GI-PROMIS domains hold potential as important PRO measures in IBD subjects. This is especially important as there is a need for improved treatment endpoints in clinical IBD management and in IBD clinical trials.

#### ACKNOWLEDGMENTS

This research was supported by grants from the Crohn's and Colitis Foundation of America, National Institutes of Health (T32DK07634, P30 DK034987) and the Patient Centered Outcomes Research Institute.

#### CONFLICT OF INTEREST

**Guarantor of the article:** Millie D. Long, MD, MPH.

**Specific Author Contributions:** Bharati Kochar: interpreting data & drafting the manuscript. Christopher F. Martin: conducting the study, collecting and interpreting data. Michael D. Kappelman: planning/conducting the study, collecting/interpreting data and drafting the manuscript. Brennan M. Spiegel: planning the study. Wenli Chen:

collecting the data. Robert S. Sandler: planning the study, drafting the manuscript. Millie D. Long: planning/conducting the study, collecting/interpreting data and drafting the manuscript.

**Financial Support:** This research was supported by grants from the Crohn's and Colitis Foundation of America, National Institutes of Health (T32DK07634, P30 DK034987) and the Patient Centered Outcomes Research Institute.

**Potential competing interests:** Michael D. Kappelman: Research support from Abbvie and Janssen, consultant to Abbvie and Janssen. Brennan M. Spiegel: Research support from Astra-Zeneca, Commonwealth Laboratories, GI Logic, Ironwood Pharmaceuticals, Nestle Health Sciences, Novartis, Shire, Takeda; Consultant for Allergan, Commonwealth Laboratories, Ironwood Pharmaceuticals, Synergy Pharmaceuticals; Royalties from GI Logic and My Total Health; Ownership My Total Health. Millie D. Long: Consultant Abbvie, Takeda, Theravance. Pfizer. The remaining authors declare no conflict of interest.

### Study Highlights

#### WHAT IS CURRENT KNOWLEDGE

- ✓ Inflammatory bowel diseases (IBD) subjects frequently report diarrhea and abdominal pain.
- ✓ IBD subjects have increased depression and anxiety.
- ✓ Patient reported outcomes (PROs) are important factors in understanding the burden of IBD.

#### WHAT IS NEW HERE

- ✓ Gastrointestinal (GI) symptoms, such as reflux and disrupted swallowing, are also commonly reported in IBD.
- ✓ Among IBD subjects experiencing GI symptoms, worsened GI symptoms correlate with worsened depression and anxiety.
- ✓ Among IBD subjects experiencing GI symptoms, narcotic use and corticosteroid use are associated with worsened GI symptoms.
- ✓ GI-PROMIS (Gastrointestinal PRO measurement information system) scales correlate with other validated measures of disease activity and quality of life in IBD.

#### REFERENCES

1. Zaharie R, Tantau A, Zaharie F *et al*. Diagnostic delay in Romanian patients with inflammatory bowel disease: risk factors and impact on the disease course and need for surgery. *J Crohns Colitis* 2016;10:306–14.
2. Maconi G, Orlandini L, Asthana AK *et al*. The impact of symptoms, irritable bowel syndrome pattern and diagnostic investigations on the diagnostic delay of Crohn's disease: A prospective study. *Dig Liver Dis* 2015;47:646–51.
3. Danese S, Fiorino G, Mary JY *et al*. Development of red flags index for early referral of adults with symptoms and signs suggestive of Crohn's disease: an IOIBD initiative. *J Crohns Colitis* 2015;9:601–6.
4. Heikenen JB, Werlin SL, Brown CW *et al*. Presenting symptoms and diagnostic lag in children with inflammatory bowel disease. *Inflamm Bowel Dis* 1999;5:158–60.
5. Haapamaki J, Turunen U, Roine RP *et al*. Impact of demographic factors, medication and symptoms on disease-specific quality of life in inflammatory bowel disease. *Qual Life Res* 2009;18:961–9.
6. Jelsness-Jorgensen LP, Bernklev T, Moum B. Coexisting irritable bowel-like symptoms in inflammatory bowel disease in remission is associated with

- impaired social functioning and increased bodily pain. *Gastroenterol Nurs* 2014;37:280–7.
7. Sun H, Lee JJ, Papadopoulos EJ *et al.* Alternate endpoints and clinical outcome assessments in pediatric ulcerative colitis registration trials. *J Pediatr Gastroenterol Nutr* 2014;58:12–17.
  8. Fausel R, Afzali A. Biologics in the management of ulcerative colitis—comparative safety and efficacy of TNF-alpha antagonists. *Ther Clin Risk Manag* 2015;11:63–73.
  9. Bruining DH, Sandborn WJ. Do not assume symptoms indicate failure of anti-tumor necrosis factor therapy in Crohn's disease. *Clin Gastroenterol Hepatol* 2011;9:395–9.
  10. Scholmerich J. Review article: should we treat symptoms or lesions in Crohn's disease? The case for treating symptoms. *Aliment Pharmacol Ther* 2006;24(Suppl 3):33–6.
  11. Mahadev S, Young JM, Selby W *et al.* Self-reported depressive symptoms and suicidal feelings in perianal Crohn's disease. *Colorectal Dis* 2012;14:331–5.
  12. Pirinen T, Kolho KL, Ashorn M *et al.* Sleep and emotional and behavioral symptoms in adolescents with inflammatory bowel disease. *Sleep Disord* 2014;2014:379450.
  13. Ananthakrishnan AN, Khalili H, Pan A *et al.* Association between depressive symptoms and incidence of Crohn's disease and ulcerative colitis: results from the Nurses' Health Study. *Clin Gastroenterol Hepatol* 2013;11:57–62.
  14. Gaines LS, Slaughter JC, Horst SN *et al.* Association between affective-cognitive symptoms of depression and exacerbation of Crohn's disease. *Am J Gastroenterol* 2016;111:864–70.
  15. Gray WN, Denson LA, Baldassano RN *et al.* Treatment adherence in adolescents with inflammatory bowel disease: the collective impact of barriers to adherence and anxiety/depressive symptoms. *J Pediatr Psychol* 2012;37:282–91.
  16. Spiegel BM, Hays RD, Bolus R *et al.* Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales. *Am J Gastroenterol* 2014;109:1804–14.
  17. Long MD, Kappelman MD, Martin CF *et al.* Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): methodology and initial results. *Inflamm Bowel Dis* 2012;18:2099–106.
  18. Kappelman MD, Long MD, Martin CF *et al.* Evaluation of the patient-reported outcomes measurement information system in a large cohort of patients with inflammatory bowel diseases. *Clin Gastroenterol Hepatol* 2014;12:1315–23 e2.
  19. Yost KJ, Eton DT, Garcia SF *et al.* Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients. *J Clin Epidemiol* 2011;64:507–16.
  20. Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. *Am J Gastroenterol* 1996;91:1571–8.
  21. Thia K, Faubion WA, Loftus EV *et al.* Short CDAI: development and validation of a shortened and simplified Crohn's disease activity index. *Inflamm Bowel Dis* 2011;17:105–11.
  22. Almario CV, Chey WD, Khanna D *et al.* Impact of National Institutes of Health Gastrointestinal PROMIS Measures in Clinical Practice: Results of a Multicenter Controlled Trial. *Am J Gastroenterol* 2016;111:1546–56.
  23. Nobrega AC, Ferreira BR, Oliveira GJ *et al.* Dyspeptic symptoms and delayed gastric emptying of solids in patients with inactive Crohn's disease. *BMC Gastroenterol* 2012;12:175.
  24. Simren M, Axelsson J, Gillberg R *et al.* Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. *Am J Gastroenterol* 2002;97:389–96.
  25. Singh S, Blanchard A, Walker JR *et al.* Common symptoms and stressors among individuals with inflammatory bowel diseases. *Clin Gastroenterol Hepatol* 2011;9:769–75.
  26. Houtveen JH, Oei NY. Recall bias in reporting medically unexplained symptoms comes from semantic memory. *J Psychosom Res* 2007;62:277–82.
  27. Camara RJ, Schoepfer AM, Pittet V *et al.* Swiss Inflammatory Bowel Disease Cohort Study, Group. Mood and nonmood components of perceived stress and exacerbation of Crohn's disease. *Inflamm Bowel Dis* 2011;17:2358–65.
  28. Ghosh S, Mitchell R. Impact of inflammatory bowel disease on quality of life: Results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey. *J Crohns Colitis* 2007;1:10–20.
  29. Long MD, Barnes EL, Herfarth HH *et al.* Narcotic use for inflammatory bowel disease and risk factors during hospitalization. *Inflamm Bowel Dis* 2012;18:869–76.
  30. Lichtenstein GR, Feagan BG, Cohen RD *et al.* Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. *Clin Gastroenterol Hepatol* 2006;4:621–30.
  31. Cross RK, Wilson KT, Binion DG. Narcotic use in patients with Crohn's disease. *Am J Gastroenterol* 2005;100:2225–9.
  32. Palm O, Moum B, Jahnsen J *et al.* Fibromyalgia and chronic widespread pain in patients with inflammatory bowel disease: a cross sectional population survey. *J Rheumatol* 2001;28:590–4.
  33. Randell RL, Long MD, Cook SF *et al.* Validation of an internet-based cohort of inflammatory bowel disease (CCFA partners). *Inflamm Bowel Dis* 2014;20:541–4.